title: Recurrence and survival analysis of resected soft tissue sarcomas of pelvic retroperitoneal structures.
abstract: BACKGROUND
  The purpose is to determine the clinicopathologic factors related to survival and recurrence of primary resected pelvic soft tissue sarcomas (STS).
  
  
  METHODS
  Demographic/clinical variables were recorded.
  
  
  RESULTS
  Thirty-five pts were identified. Median follow-up was 24.2 months. There were 23 (65.7%) high/intermediate-grade and 12 (34.3%) low-grade tumors included in the final analysis. Eight patients (22.9%) received neoadjuvant therapy. Margins were grossly negative in 27 (77.1%, 17-R0, 10-R1) and grossly positive (R2) in 8 (22.9%). Adjuvant therapy was used in 13 patients (37.1%). The 2- and 3-year RFS was 56.5% and 51.3%, with 14 patients recurring at a median time of 16 months (6-local, 8-distant). All distant recurrences were in high-grade tumors. There were no differences in RFS for margins (R0 vs. R1), neoadjuvant/adjuvant therapy, size (≥10 vs. <10 cm) or gender. High/intermediate-grade tumors had worse RFS (P < 0.008). The 2- and 3-year OS was 80.9%. OS was improved for R0/R1 resection (P < 0.001). Resection to R0/R1 margin was a significant predictor of improved OS (P = 0.001).
  
  
  CONCLUSIONS
  High/intermediate-grade lesions were associated with worse OS and RFS. Resection to gross negative margins was the only independent predictor of OS. Adjuvant therapy may be reserved for high-grade lesions due to increased metastatic potential. J
authors.affiliation: Department of Sarcoma, Moffitt Cancer Center, Tampa, Florida.
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Doepker
authors.affiliation: University of South Florida Medical School, Tampa, Florida.
authors.forename: Karim H
authors.initials: KH
authors.lastname: Hanna
authors.affiliation: Department of Biostatistics, Moffitt Cancer Center, Tampa, Florida.
authors.forename: Zachary J
authors.initials: ZJ
authors.lastname: Thompson
authors.affiliation: Department of Sarcoma, Moffitt Cancer Center, Tampa, Florida.
authors.forename: Odion T
authors.initials: OT
authors.lastname: Binitie
authors.affiliation: Department of Sarcoma, Moffitt Cancer Center, Tampa, Florida.
authors.forename: Douglas G
authors.initials: DG
authors.lastname: Letson
authors.affiliation: Department of Sarcoma, Moffitt Cancer Center, Tampa, Florida.
authors.forename: Ricardo J
authors.initials: RJ
authors.lastname: Gonzalez
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant; D015986:Confounding Factors, Epidemiologic; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000628:therapy*; D010386:Pelvic Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D011237:Predictive Value of Tests; D018714:Radiotherapy, Adjuvant; D012186:Retroperitoneal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D012189:Retrospective Studies; D012307:Risk Factors; D012509:Sarcoma / Q000401:mortality* / Q000473:pathology / Q000601:surgery* / Q000628:therapy
keywords: clinicopathologic factors; neoadjuvant therapy; resection margins